Accuray Reports Second Quarter Fiscal 2021 Financial Results

The MarketWatch News Department was not involved in the creation of this content.

SUNNYVALE, Calif., Jan. 27, 2021 /PRNewswire via COMTEX/ —
SUNNYVALE, Calif., Jan. 27, 2021 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the second quarter of fiscal 2021 ended December 31, 2020.

  • Net revenue of $97.5 million including $21.3 million of system revenue in China

  • Gross orders of $75.4 million, ending backlog of $596.2 million, an increase of 11 percent from December 31, 2019

  • GAAP operating income of $8.2 million and GAAP net income of $4.8 million compared to GAAP operating income of $3.6 million and GAAP net income of $10.7 million in the prior year second quarter

  • Adjusted EBITDA grew to $13.5 million from $7.1 million in the prior year second quarter

  • Received 510(k) FDA clearance for ClearRT™ Helical kVCT Imaging for the Radixact® System

“Our second quarter performance continues to reflect the positive momentum our business is making despite the headwinds created by the COVID-19 environment, said Josh Levine, President and CEO of Accuray. “Highlights from our second quarter performance include the beginning of system revenue conversion related to the Type A radiotherapy licenses in China as well as receiving 510(k) FDA clearance of our ClearRT Helical kVCT Imaging platform for the Radixact System. We are pleased with the continued resilience and commercial cadence that our business is exhibiting as well as the recent product innovation/upgrades coming through our development pipeline. We believe the additions of the Cyberknife S7 System, Synchrony on Radixact, and ClearRT Helical kVCT Imaging to our portfolio will have meaningful clinical impact for our customers and we look forward to the adoption of these important features and the functional improvement they represent in clinical practice.”

Fiscal Second Quarter Results Gross orders totaled $75.4 million compared to $98.6 million for the prior fiscal year period. Backlog as of December 31, 2020 was $596.2 million, an increase of 11 percent compared to $539.4 million for the prior fiscal year period. Total net revenue was $97.5 million compared to $98.8 million in the same prior fiscal year period. Product revenue totaled $41.8 million compared to $43.8 million in the same prior fiscal year period, while service revenue totaled $55.7 million compared to $55.1 million in the same prior fiscal year period. Total gross profit for the fiscal 2021 second quarter was $40.8 million, or 41.9 percent of net revenue, comprised of product gross margin of 44.7 percent of product revenue and service gross margin of 39.8 percent of service revenue. This compares to total gross profit of $37.9 million, or 38.4 percent of net revenue, comprised of product gross margin of 44.0 percent of product revenue and service gross margin of 33.9 percent of service revenue in the prior fiscal year second quarter. Operating expenses were $32.6 million, a decrease of 5 percent compared to $34.3 million in the prior fiscal year second quarter.

Net income was $4.8 million, or $0.05 per share, compared to a net income of $10.7 million, or $0.12 per share, in the same prior fiscal year period. The prior year second quarter net income included a non-cash, special gain of $13.0 million related to the value of the Company’s capital contribution to the Company’s China joint venture. This gain was recorded as non-operating, other income in the prior fiscal year second quarter.

Adjusted EBITDA for the second fiscal quarter 2021 was $13.5 million compared to $7.1 million in the same prior fiscal year period, which excludes the non-cash, special gain related to the Company’s capital contribution to the China joint venture recorded in the prior fiscal year second quarter. Cash, cash equivalents and short-term restricted cash were $116.0 million as of December 31, 2020 compared with $95.5 million as of September 30, 2020. Fiscal Six Months Results

For the six months ended December 31, 2020, gross product orders totaled $125.9 million compared to $177.0 million in the same prior fiscal year period. Ending product backlog was $596.2 million, approximately 11 percent higher than backlog at the end of the prior fiscal year second quarter.

Total net revenue for the six months ended December 31, 2020 was $182.8 million compared to $188.4 million in the same prior fiscal year period. Product revenue for the six months ended December 31, 2020 totaled $73.1 million compared to $81.4 million, while service revenue totaled $109.7 million compared to $107.0 million in the same prior fiscal year period.

Total gross profit for the six months ended December 31, 2020 was $76.2 million, or 41.7 percent of net revenue, comprised of product gross margin of 43.2 percent of product revenue and service gross margin of 40.7 percent of service revenue. This compares to total gross profit of $70.8 million, or 37.6 percent of net revenue, comprised of product gross margin of 43.4 percent of product revenue and service gross margin of 33.2 percent of service revenue in the same prior fiscal year period.

Operating expenses for the six months ended December 31, 2020 were $62.6 million, a decrease of 12 percent compared with $71.5 million in the same prior fiscal year period.

Net income was $5.2 million, or $0.06 per share, for the six months ended December 31, 2020, compared to net income of $1.4 million, or $0.02 per share, in the same prior fiscal year period.  The prior year six month period ended December 31, 2019 included a non-cash, special gain of $13.0 million related to the value of the Company’s capital contribution to the Company’s China joint venture. The gain was recorded as non-operating, other income in the prior fiscal year second quarter.

Adjusted EBITDA for the six months ended December 31, 2020 was $22.5 million, compared to $6.1 million in the prior fiscal year period, which excludes the non-cash, special gain related to the Company’s capital contribution to the China joint venture recorded in the prior fiscal year second quarter.

Financial Guidance The impact of the COVID-19 pandemic on Accuray’s fiscal 2021 results remains uncertain. Given the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry, Accuray believes it is prudent to refrain from providing financial guidance for fiscal year 2021.

Conference Call Information Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the second quarter of fiscal 2021 as well as recent corporate developments. Conference call dial-in information is as follows:

  • U.S. callers: (877) 270-2148

  • International callers: (412) 902-6510

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray’s website, www.accuray.com.

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call’s conclusion and will be available for seven days. The replay telephone number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 10151157. An archived webcast will also be available at Accuray’s website until Accuray announces its results for the third quarter of fiscal 2021.

Use of Non-GAAP Financial Measures

Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, gain on contribution to equity method investment in joint venture and stock-based compensation (“adjusted EBITDA”). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

There are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the Company’s future results of operations, including expectations regarding gross orders, order volume and age-outs; expectations regarding the effect of the COVID-19 pandemic on the Company; the Company’s ability to adapt and make the necessary adjustments to compete and operate effectively; the Company’s continued resilience and ability to continue to realize the benefits of working capital management and cash preservation activities; expectations regarding future sales in China; expectations regarding the Company’s Chinese joint venture, including the timing of and ability to drive revenue conversion and introduce a Type B product to the market in China as well as the operating impact of the joint venture on the Company’s income statement; expectations regarding the Company’s product innovations and developments, including expectations related to future regulatory approvals; expectations regarding the Company’s product portfolio, the clinical impact and value of those products on our customers, and market adoption of such products, including with respect to the Company’s Synchrony on Radixact, CyberKnife S7 System and Clear RT Helical kVCT Imaging upgrades as well as other strategic product innovations; expectations regarding the commercial launch of Clear RT Helical kVCT Imaging; expectations regarding the new Centers for Medicare and Medicaid Services alternative payment model and reimbursement schedule; expectations regarding the future of radiotherapy treatment; and the Company’s leadership position in radiation oncology innovation and technologies.  These forward-looking statements involve risks and uncertainties.  If any of these risk or uncertainties materialize, or if any of the Company’s assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements.  These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the Company and those of its customers and suppliers; the Company’s ability to achieve widespread market acceptance of its products, including new product and software offerings; the Company’s ability to develop new products or enhance existing products to meet customers’ needs and compete favorably in the market, the Company’s ability to effectively integrate and execute the joint venture, the Company’s ability to realize the expected benefits of the joint venture; the ability of customers in China to obtain Class A or B user licenses to purchase radiotherapy systems; risks inherent in international operations; the Company’s ability to effectively manage its growth; the Company’s ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the Company’s ability to meet the covenants under its credit facilities; the Company’s ability to convert backlog to revenue; and such other risks identified under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2020 and as updated periodically with the Company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events.  The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Accuray Incorporated

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

Three Months Ended

December 31,

Six Months Ended

December 31,

2020

2019

2020

2019

Gross Orders

$

75,365

$

98,556

$

125,893

$

177,043

Net Orders

42,462

89,904

66,016

128,885

Order Backlog

596,214

539,357

596,214

539,357

Net revenue:

Products

$

41,805

$

43,760

$

73,063

$

81,365

Services

55,654

55,066

109,728

107,038

Total net revenue

97,459

98,826

182,791

188,403

Cost of revenue:

Cost of products

23,102

24,518

41,528

46,088

Cost of services

33,526

36,408

65,029

71,472

Total cost of revenue

56,628

60,926

106,557

117,560

Gross profit

40,831

37,900

76,234

70,843

Operating expenses:

Research and development

11,956

13,064

24,104

26,405

Selling and marketing

10,348

11,327

19,246

24,593

General and administrative

10,328

9,886

19,217

20,502

Total operating expenses

32,632

34,277

62,567

71,500

Income (loss) from operations

8,199

3,623

13,667

(657)

Income on equity investment, net

1,117

1,089

Other income (expense), net

(4,260)

7,766

(8,954)

3,327

Income before provision for income taxes

5,056

11,389

5,802

2,670

Provision for income taxes

287

679

631

1,316

Net income

$

4,769

$

10,710

$

5,171

$

1,354

Net income per share – basic

$

0.05

$

0.12

$

0.06

$

0.02

Net income per share – diluted

$

0.05

$

0.12

$

0.06

$

0.02

Weighted average common shares used in

   computing income per share:

Basic

92,025

89,517

91,609

89,145

Diluted

93,353

90,279

92,607

90,095

 

 

Accuray Incorporated

Condensed Consolidated Balance Sheets

(in thousands)

(Unaudited)

December 31,

June 30,

2020

2020

Assets

Current assets:

Cash and cash equivalents

$

107,322

$

107,577

Restricted cash

8,692

997

Accounts receivable, net

65,367

90,599

Inventories

138,655

134,374

Prepaid expenses and other current assets

22,309

21,227

Deferred cost of revenue

2,577

2,712

Total current assets

344,922

357,486

Property and equipment, net

13,773

15,349

Investment in joint venture

17,019

13,929

Goodwill

57,963

57,717

Intangible assets, net

549

663

Operating lease right-of-use assets

26,110

28,647

Other assets

17,806

17,136

Total assets

$

478,142

$

490,927

Liabilities and equity

Current liabilities:

Accounts payable

$

10,876

$

23,126

Accrued compensation

21,942

17,963

Operating lease liabilities, current

8,587

8,224

Other accrued liabilities

24,396

27,180

Customer advances

19,516

22,571

Deferred revenue

80,884

83,207

Short-term debt

12,530

Total current liabilities

178,731

182,271

Long-term other liabilities

9,195

7,416

Deferred revenue

23,391

24,125

Operating lease liabilities, non-current

20,965

24,173

Long-term debt

168,082

189,307

Total liabilities

400,364

427,292

Equity:

Common stock

93

91

Additional paid-in capital

551,409

545,741

Accumulated other comprehensive income (loss)

2,818

(484)

Accumulated deficit

(476,542)

(481,713)

Total equity

77,778

63,635

Total liabilities and equity

$

478,142

$

490,927

 

 

Accuray Incorporated

Reconciliation of GAAP Net Income to Adjusted Earnings Before Interest, Taxes, Depreciation,

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)

Three Months Ended

December 31,

Six Months Ended

December 31,

2020

2019

2020

2019

GAAP net income

$

4,769

$

10,710

$

5,171

$

1,354

Depreciation and amortization

1,663

1,846

3,313

3,697

Stock-based compensation

2,364

2,149

4,608

3,849

Interest expense, net

4,430

4,683

8,823

8,883

Gain on contribution to equity method investment in joint venture (a)

(12,965)

(12,965)

Provision for income taxes

287

679

631

1,316

Adjusted EBITDA

$

13,513

$

7,102

$

22,546

$

6,134

(a) Consists of non-cash gain related to the value of the Company’s capital contribution to the China joint venture.

 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-reports-second-quarter-fiscal-2021-financial-results-301216554.html

SOURCE Accuray Incorporated

COMTEX_379693922/2454/2021-01-27T16:05:25

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

The MarketWatch News Department was not involved in the creation of this content.

About Megan B. Schulze

Check Also

How to Invest in Stocks of SOS Limited China

  This is a short article on how to invest in stocks of SOS Limited. SOS is a Chinese firm that is one of the largest foreign-owned businesses in the world. As I write this article, it is trade revenues in China that are exceeding US exports. I will explain to you the stock analysis …